Learn more As a plus-size woman, I know the struggle of finding great clothing in extended sizes. Fortunately, where once there were only two or three retailers catering to plus sizes, now there ...

AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth. But in the near term ...

Below we've highlighted some notable scores on designer shoes, bags, and clothing from our favorite online luxury retailers — because everyone loves a good deal, whatever their budget may be.

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen for $10 billion last year), Sutro thinks its "best in class" candidate ...

A newer addition to AbbVie's portfolio is Elahere, approved for the treatment of numerous cancers, including epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...